



Preferred Drug List

NEW DRUG REVIEW

Proprietary Name: Zelapar™ Orally Disintegrating Tablets

Common Name: Selegiline HCl

PDL Category: Anti-Parkinsonian Drugs

<u>Comparable Products</u>	<u>Preferred Drug List/ Recommended Drug List Status</u>
Carbidopa-Levodopa	Preferred
Selegiline HCl Cap 5 mg	Preferred
Selegiline HCl Tab 5 mg	Preferred

Summary

Indications and Usage: To be used adjunctively with carbidopa/levodopa in the treatment of Parkinson's Disease

Dosage Forms: Orally disintegrating tablets, 1.25mg

Recommended Dosage: 1.25mg tablet daily for six weeks; may increase to 2.5mg daily if necessary. Maximum recommended dose is 2.5mg

Common Adverse Drug Reactions: Nausea, dizziness, headache, insomnia, rhinitis, dyskinesia, stomatitis, back pain, dyspepsia

Contraindications: Hypersensitivity to any component of selegiline, concomitant use of dextromethorphan, methadone, propoxyphene, tramadol, other use of MAOIs.

Manufacturer: Valeant Pharmaceuticals International

Analysis: Zelapar™ takes advantage of a disintegrating tablet delivery system to distribute more active drug at a lower dose, thus reducing adverse drug reactions. Early studies show that Zelapar™ reduces the "off" time of carbidopa/levodopa by 2.2 hours per day on average. There is no evidence, from controlled studies, that Zelapar™ has any clinical benefit in the absence of concurrent carbidopa/levodopa therapy. Current market analysis show the majority of Iowa Medicaid members with Parkinson's who use selegiline use it alone without concurrent carbidopa/levodopa therapy. If combination therapy is required, other forms of selegiline are available as preferred medications on the Preferred Drug List that are equally efficacious and more cost effective than Zelapar™

IME Recommendation:

<input type="checkbox"/>	Preferred Drug	<input type="checkbox"/>	Recommended Drug
<input checked="" type="checkbox"/>	Non-Preferred Drug	<input type="checkbox"/>	Non-Recommended Drug
<input type="checkbox"/>	Preferred Drug with Conditions		